succinylcholine has been researched along with edrophonium bromide in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Agnusdei, M; Belinskaya, T; Borriello, M; Brindisi, M; Butini, S; Campiani, G; Catalanotti, B; Fattorusso, C; Fiorini, I; Gemma, S; Nacci, V; Novellino, E; Panico, A; Persico, M; Ros, S; Saxena, A | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
2 other study(ies) available for succinylcholine and edrophonium bromide
| Article | Year |
|---|---|
Exploiting protein fluctuations at the active-site gorge of human cholinesterases: further optimization of the design strategy to develop extremely potent inhibitors.
Topics: Acetylcholinesterase; Binding Sites; Butyrylcholinesterase; Cholinesterase Inhibitors; Computational Biology; Crystallography, X-Ray; Drug Design; Humans; Models, Molecular; Protein Conformation; Structure-Activity Relationship; Tacrine | 2008 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |